1. Home
  2. FT vs ELTX Comparison

FT vs ELTX Comparison

Compare FT & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Universal Trust

FT

Franklin Universal Trust

HOLD

Current Price

$7.91

Market Cap

199.8M

Sector

Finance

ML Signal

HOLD

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

BUY

Current Price

$3.22

Market Cap

185.4M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
FT
ELTX
Founded
1988
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
199.8M
185.4M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
FT
ELTX
Price
$7.91
$3.22
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$18.00
AVG Volume (30 Days)
29.0K
662.1K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
7.85%
N/A
EPS Growth
N/A
39.29
EPS
N/A
N/A
Revenue
N/A
$2,301,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.79
$2.66
52 Week High
$8.35
$16.00

Technical Indicators

Market Signals
Indicator
FT
ELTX
Relative Strength Index (RSI) 36.98 41.71
Support Level $7.84 $2.72
Resistance Level $8.08 $5.38
Average True Range (ATR) 0.06 0.20
MACD -0.01 0.23
Stochastic Oscillator 13.09 81.25

Price Performance

Historical Comparison
FT
ELTX

About FT Franklin Universal Trust

Franklin Universal Trust is a closed-end management investment company focused on providing high current income while preserving capital. Its secondary objective is to achieve income growth through dividend increases and capital appreciation. The fund invests in two asset classes: high-yield bonds and utility stocks. It applies fundamental research to build a diversified high-yield bond portfolio and targets utility companies with attractive dividend yields and a history of increasing dividends.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

Share on Social Networks: